Nevertheless, among the top SNP variations in both trials were those associated with drug metabolism/detoxification/transport, including: cyp genes, multiple variants of GSTA4, SLCO, UGT1, NAT2, ABCB genes; as well as genes impacting cellular response, including: BMP2 (inducing myeloma apoptosis), cathepsin B (inducing IL-8 dependent cellular migration and angiogenesis [31,32], XRCC5 (DNA repair); and genes associated with proliferative responses (PCNA, MAPK, cyclin kinase). Here, XRCC5 is linked to plasma cell myeloma.